



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated:--14-06-2008

Mr. Yasin Tahir,
Director General, IPO-Pakistan
Islamabad.

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 24-5-2008 TO BE PUBLISHED 16-06-2008 IN
THE GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 14-06-2008

To,

Mr. Manzoor Ahmed
Section Officer
Cabinet Secretariat
Cabinet Division
Government of Pakistan
Islamabad

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 24-5-2008 TO BE PUBLISHED 16-06-2008 IN
THE GAZETTE OF PAKISTAN PART-V.**

Reference to Cabinet Secretariats letter No. 18/IPO/2008/RA-IV, dated 23rd April 2008. A manuscript copy of the weekly notification regarding application filed, application accepted and sealing fee due etc., is enclosed herewith for onward transmission to the Printing Corporation of Pakistan Press for publication in the next issue of the Gazette of Pakistan Part-V.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

552/2008	<u>19-5-2008</u> Syngenta Participations AG, Switzerland (Priority 31-5-07 Europe)	“Process for the production of pyrazoles”
553/2008	Snamprogetti S.P.A. Italy (Priority 22-5-07 Italy)	“Enhanced process for the synthesis of urea”
554/2008	Mitsubishi Heavy Industries, Ltd. Japan	“Exhaust gas desulfurizer”
555/2008	Mitsubishi Heavy Industries, Ltd. Japan	“Exhaust gas desulfurizer”
556/2008	Mitsubishi Heavy Industries, Ltd. Japan	“Foam recovery device and foam recovery system”
557/2008	<u>20-5-2008</u> Ch. M. Akhtar, Rawalpindi, Pakistan	“Development of cross pilot reaction turbine, and hydraulic speed governor”
558/2008	Cypress Bioscience, Inc. USA (Priority 22-5-07 USA)	“Method for improving physical function in fibromyalgia”
559/2008	Wyeth, USA (Priority 22-5-07 USA)	“Improved processes for making hydrazides”
560/2008	World Wide Stationery Manufacturing Company Ltd. Hong Kong (Priority 22-3-05 USA)	“A ring mechanism for holding loose-leaf pages”
561/2008	Eli Lilly and Company, USA (Priority 30-5-07 USA)	“Cyclic peptide CXCR4 antagonists”

	<u>21-5-2008</u>	
562/2008	1.Otsuka Pharmaceutical Co. Ltd., 2. Juntendo Universit, Japan (Priority 22-5-07 Japan)	“A medicament for treating alzheimer’s disease”
563/2008	Saudi Basic Industries Corporation, Saudi Arabia (Priority 23-5-07 Europe)	“Process for oxidative dehydrogenation using a boria-alumina catalyst”
564/2008	Eisai R& D Management Co. Ltd., Japan (Priority 03-5-05 USA) Divisional	“((2R-3R)-3-(4-(4-cyano-phenyl)thiazol-2-yl)-2-(2,4-difluorophenyl)-1-(1H, 1, 2, 4-triazol-1-yl] bufan-2-yloxy) methyl dihydrogen phosphate”
565/2008	Eisai R& D Management Co. Ltd., Japan (Priority 03-5-05 USA) Divisional	“((2R-3R)-3-(4-(4-cyano-phenyl)thiazol-2-yl)-2-(2,4-difluorophenyl)-1-(1H, 1, 2, 4-triazol-1-yl] bufan-2-yloxy) methyl dihydrogen phosphate”
566/2008	AstraZeneca AB, Sweden (Priority 19-10-05 GB) Divisional	“Benzamide compound”
	<u>22-5-2008</u>	
567/2008	Muhammad Yasin Khan PCSIR, Karachi	“Khan’s solar still”
568/2008	1. Syed Burhanuddin Abdali, 2. Z. A. Dhakan, 3. Muhammad Adil and 4. Mohsin Ali PCSIR, Karachi. Pakistan	“A process for the production of magnesium carbonate form sea bittern”
569/2008	Muhammad Yasin Khan PCSIR, Karachi	“Khan’s global clock”
570/2008	The Regents of the University of California, USA (Priority 13-11-07 USA)	“Atmospheric pressure plasma induced graft polymerization “

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.


Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

812/1998	SmithKLine Beecham Corporation. USA.	“(E)- α -[2-N-Butyl-1-[(4-Carboxyphenyl) Methyl]-1H-imidazol-5-yl] Methylene-2-Thiophenepropionic Acid”	139560
		(INT: CL, C07D 233/04)	

This invention relates to (E)-Alpha-[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid arginyl, charge-neutralization-complex composition containing the compound and method of using the compound to block angiotensin II receptors and to treat hypertension, congestive heart failure and renal failure.

250/2002	Janssen Pharmaceutica N.V. Belgium.	“Lipid Lowering Biphenylcarboxamide”	139561
		(INT: CL, Co7D 295/15)	

Biphenylcarboxamide compound of formula (I)




method for preparing such compound, pharmaceutical

composition comprising said compound as well as the use of said compound as a medicine for the treatment of hyperlipiderma, obesity and type II diabetes.

461/2002 Glaxo Group Limited.
United Kingdom. “Thiazole Compound”
(C07D 277/30)

139562

A compound of formula (I) solvate and hydrolysable ester thereof



Wherein

X¹ represents O or S; R¹ and R² are independently H or C₁₋₃ alkyl or R¹ and R² which are bonded to the same carbon atom may together with the carbon atom to which they are bonded form a 3-5 membered cycloalkyl ring; R³ and R⁴ independently represent H, halogen, -CH₃ and -OCH₃; R⁵ represents H or C₁₋₆ alkyl X₂ represents NH, NCH₃ or O: One of Y and Z is N, and the other is O or S; R₆ represents phenyl or pyridyl (wherein the N is in position 2 or 3) and is optionally substituted by one or more halogen, CF₃, C₁₋₆ straight or branched alkyl (optionally substituted by halogen), with the provision that when R₆ is pyridyl, the N is unsubstituted.

664/2002 GlaxoSmithKline Biologicals S.A. and Glaxo Group Ltd.
United Kingdom. “Composition Comprising an HIV TAT Protein”
(C12N 15/11)

139563

Use of a) an HIV Tat protein or polynucleotide; or b) an HIV Nef protein or polynucleotide; or c) an HIV Tat protein or polynucleotide linked to an HIV Nef protein or polynucleotide; and an HIV gp 120 protein or polynucleotide in the manufacture of a vaccine suitable for a prime-boost delivery for the prophylactic or therapeutic immunisation of humans against HIV, wherein the protein or polynucleotide is delivered via a bombardment approach.


753/2002 Alizyme
Therapeutics
Limited.
United Kingdom.

“Thieno-[1, 3]-oxazin-4-one”

(C07D 265/12,333/50)

139564

The compound comprising formula (I):



For use in the treatment of obesity and related disorders. The invention also relates to novel compounds within formula (I), and pharmaceutical compositions containing them. In formula (I): A is an optionally substituted thienyl moiety, Y is O, S, or NR², R¹ is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups and R² is hydrogen or a group as defined for R¹.

988/2002 Pharmacia &
Upjohn
Company.
USA.

“Substituted Aryl 1, 4-Pyrazine Compound

(C07D 241/42 A61K 31/4985)

139565

Substituted aryl 1,4-pyrazine compound and their use in treating anxiety disorders, depression and stress related disorders are disclosed.


769/2006 Wyeth Holdings
Corporation.
USA.

“Pharmaceutically Acceptable Salt of Tricyclic Benzazepine”

(C07D 223/16 A61K 31/55)

139566

A pharmaceutically acceptable salt of the Tricyclic compound of the general Formula I:



as defined herein which exhibit antagonist activity at V1 and/or V2 receptors and exhibit in VIVO vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reab-sorption of water, and process for preparing such compound.

BBBBBBBBBB

REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2)
RULE 37(b) OF THE PATENTS ORDINANCE 2000

In the matter of Patent No. 138419 of 7-2-2003 Priority Date 8-2-2002 (Germany). Granted to:- **Zimmer AG.**, a German company, Borsigallee 1, D-60388 Frankfurt am Main, Germany.

In pursuance of an application received on 01-12-2007.

The following entry has been made in the Register of Patents:-

Lurgi Zimmer GmbH, a German company having its office at Lurgiallee 5, 60295 Frankfurt am Main, Germany as proprietor by virtue of Deed of Assignment dated 21st September, 2007 made between **Zimmer AG**, as Assignor of the ONE PART and **Lurgi Zimmer GmbH** as Assignee of the OTHER PARTS.

PROCEEDING UNDER SECTION 45 OF THE ORDINANCE 2000.

Notice is hereby given that an application under section 45 of the Patents Ordinance, 2000 for restoration of a lapsed Patent No. 138528, dated: 28-4-2003 Priority date 06-05-2002 (USA) for the invention entitled “ Process for the production of Terephthalic Acid”.

Which ceased on 06-5-2006 has been left at the Patent Office 09-12-2006 on behalf of the Patentee, E.I.DU PONT DE NEMOURS AND COMPANY, (a Delaware Corporation), of Wilmington, Delaware, United States of America.

Any person may give notice of opposition to the restoration by lodging form P-7 of the Patent Rules 2003, accompanied by the prescribed fee of Rs. 750/- of the Patent Office, 2nd Floor Kandawala Building, M.A. Jinnah Road, Karachi within two months from the date of advertisement in the Gazette.

Will appear in the Gazette. _____ 2008.

REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2)
RULE 37(b) OF THE PATENTS ORDINANCE 2000

In the matter of Patent No. 138489 of 22-3-2003 Priority Date 23-03-2002 (EPO). Granted to:- **Zimmer AG.**, a German company, Borsigallee 1, D-60388 Frankfurt am Main, Germany.

In pursuance of an application received on 01-12-2007.

The following entry has been made in the Register of Patents:-

Lurgi Zimmer GmbH, a German company having its office at Lurgiallee 5, 60295 Frankfurt am Main, Germany as proprietor by virtue of Deed of Assignment dated 21st September, 2007 made between **Zimmer AG**, as Assignor of the ONE PART and **Lurgi Zimmer GmbH** as Assignee of the OTHER PARTS.

REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE
37(b) OF THE PATENTS ORDINANCE 2000

In the matter of Patent No. 138478 of 22-3-2003 Priority Date 23-3-2002 (EPO). Granted to:- **Zimmer AG.**, a German company, Borsigallee 1, D-60388 Frankfurt am Main, Germany.

In pursuance of an application received on 01-12-2007.

The following entry has been made in the Register of Patents:-

Lurgi Zimmer GmbH, a German company having its office at Lurgiallee 5, 60295 Frankfurt am Main, Germany as proprietor by virtue of Deed of Assignment dated 21st September, 2007 made between **Zimmer AG**, as Assignor of the ONE PART and **Lurgi Zimmer GmbH** as Assignee of the OTHER PARTS.

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139313	AstraZeneca AB Sweden	746/2002
139314	LES Laboratoires Servier France	223/2005
139315	Recon Oil Industries Private Limited India	276/2005

(Mrs. Yasmeen Abbasi)

Controller of Patents

Tel: 9215488